AIDS Malignancy Clinical Trials Consortium (Limited Competition U01)

The summary for the AIDS Malignancy Clinical Trials Consortium (Limited Competition U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
AIDS Malignancy Clinical Trials Consortium (Limited Competition U01): Purpose. The purpose of this limited competition funding opportunity announcement (FOA) is to continue support of the research activities of AIDS Malignancy Consortium which are: 1) design, development, and evaluation of clinical interventions for the prevention and treatment of malignancies in patients with HIV infection; 2) development of more effective management and therapeutics for HIV-associated malignancies; 3) investigation of the biology of HIV malignancies within the context of clinical trials; 4) management of issues of international importance in HIV-associated-malignancies; and 5) distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource for ongoing or future investigations. The award will provide subcontracts for a coordinating center, core sites, affiliate sites, network laboratories and a statistical center. Sites will receive patient care costs on a capitation basis and for laboratory correlative studies, clinical pharmacology and international studies. The group will have at least four scientific disease-oriented working groups (WG) - KS, lymphoma, HPV-associated cancers, and non-AIDS-Defining Cancers (NADCs) Working Groups . Mechanism of Support. This FOA will use the NIH U01 cooperative agreement award mechanism. Funds Available and Anticipated Number of Awards. It is anticipated that $ 4.68 million for year one will be available for this initiative, and one application is expected to be awarded.
Federal Grant Title: AIDS Malignancy Clinical Trials Consortium (Limited Competition U01)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-10-502
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.393
CFDA Descriptions: Cancer Cause and Prevention Research
Current Application Deadline: Mar 03, 2010
Original Application Deadline: Mar 03, 2010
Posted Date: Dec 24, 2009
Creation Date: Dec 24, 2009
Archive Date: Apr 03, 2010
Total Program Funding: $4,680,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Public and State controlled institutions of higher education
Additional Information on Eligibility
Other Eligible Applicants include the following: The eligibility to apply in response to this limited competition FOA is limited to the current AMC Group Chair recipient institution (U01CA121947).
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...
Pilot Studies in Pancreatic Cancer
Cancer Prevention Research Small Grant Program
Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com